Effect of hyperlipidemia on endothelial VCAM-1 expression and the protective role of fenofibrate

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Endothelial Function

Background:

• Hyperlipidemia is a major risk factor for atherosclerosis.
• Endothelial dysfunction plays a critical role in the pathogenesis of atherosclerosis.
• Nitric oxide (NO) and vascular cell adhesion molecule-1 (VCAM-1) are key mediators of endothelial function and inflammation.

Purpose of the Study:

• To investigate the effects of hyperlipidemia on endothelial function.
• To evaluate the therapeutic potential of fenofibrate in mitigating hyperlipidemia-induced endothelial dysfunction.
• To examine the impact of fenofibrate on nitric oxide (NO) levels and VCAM-1 expression in hyperlipidemic rats.

Main Methods:

• Establishment of a hyperlipidemia rat model using an atherogenic diet.
• Treatment with fenofibrate (40 mg/kg/day) for 16 weeks.
• Measurement of serum lipid levels, NO levels, VCAM-1 expression, and leukocyte accumulation in aortic endothelium.

Main Results:

• Hyperlipidemia significantly reduced NO levels and increased leukocyte accumulation and VCAM-1 expression compared to controls.
• Fenofibrate treatment restored NO levels and decreased VCAM-1 expression and leukocyte accumulation in hyperlipidemic rats.
• Hyperlipidemia was shown to inhibit NO activity and promote VCAM-1-mediated endothelial damage.

Conclusions:

• Hyperlipidemia induces endothelial dysfunction through decreased NO bioavailability and increased VCAM-1 expression.
• Fenofibrate demonstrates significant potential in preventing atherosclerosis by restoring NO levels and down-regulating VCAM-1.
• Fenofibrate offers a promising therapeutic strategy for managing hyperlipidemia-associated endothelial dysfunction and atherosclerosis.